Insulin

When insulin binds to IGF-1 receptors, AKT activates mTOR (mechanistic target of rapamycin), which drives cell growth and division. Simultaneously, AKT phosphorylates and inactivates BAD (BCL2-associated agonist of cell death), preventing apoptosis. In a hyperinsulinemic state these pathways are constantly active rather than briefly pulsatile. The speaker implies this mechanism is relevant to understanding why peptides that activate similar growth pathways must be dosed carefully.

Due to structural homology between insulin and IGF-1, chronically elevated insulin spills over and binds to IGF-1 receptors throughout the body, activating the same PI3K/AKT/mTOR and MAPK proliferation cascades that IGF-1 triggers. This is cited from Dr. Michael Pollak, McGill University, 2008, published in Nature Reviews Cancer. The speaker warns this means hyperinsulinemia provides a constant 'grow, divide, survive' signal to all cells including potentially cancerous ones.

The speaker provides a mechanistic explanation of how insulin blocks fat burning by inactivating hormone-sensitive lipase (HSL), which is described as step two in the process of converting stored triglycerides in fat cells to usable ATP energy. Because fat must be mobilized from storage and transported to cells for oxidation — unlike glucose which is metabolized in situ — HSL inhibition by insulin completely prevents lipolysis. This is presented as the core biochemical reason why chronically elevated insulin prevents fat loss regardless of caloric deficit.

Insulin is described as the second most potent anabolic hormone in the human body, essential for muscle building in controlled acute circumstances. However, chronically elevated insulin is characterized as disastrous, inhibiting lipolysis via HSL suppression and driving visceral fat accumulation. The speaker frames this as an acute-versus-chronic stress adaptation principle, where the same hormone that builds muscle in short bursts destroys metabolic health when chronically elevated.

The speaker acknowledges that insulin is technically a peptide but explicitly distinguishes it from the therapeutic peptides he discusses, arguing that exogenous insulin manipulation for bodybuilding purposes is dangerous and irresponsible. He recounts a personal anecdote of a 17-year-old bodybuilder who died from exogenous insulin use. He states he does not believe therapeutic peptides manipulate biology in the same dangerous way insulin does.

The speaker explicitly acknowledges insulin is a peptide while warning about its dangers when chronically elevated. He recounts a personal anecdote of a 17-year-old bodybuilder (Phil Andre) who died from exogenous insulin use, emphasizing that manipulating insulin biology is extremely dangerous. He distinguishes this from therapeutic peptide use but uses it as a cautionary framework for all peptide manipulation.

The speaker identifies unresolved insulin resistance as the primary driver of weight regain after stopping GLP-1 agonists. He frames the solution as fixing the hormonal environment rather than increasing caloric restriction, suggesting that sustainable results require addressing insulin signaling — not just appetite suppression.

The speaker claims strategic fasting drops insulin levels faster than any other intervention and calls it one of the most powerful tools available. No fasting protocol details (duration, frequency) are provided.

When insulin is chronically elevated due to insulin resistance, hunger increases, metabolic rate drops, and fat cells become unable to release stored energy. The speaker describes a state where the body has tens of thousands of calories in reserve but cannot access them. No dosages or lab values are cited.

Dr. Jones argues that insulin's role extends far beyond blood sugar management. It drives fat into adipocytes, protein into muscle, and signals the brain regarding hunger and energy expenditure. He frames the narrow 'blood sugar only' view of insulin as the reason people rebound after stopping GLP-1 agonists.

As a direct consequence of the severe insulin resistance induced by high-dose GH use (10–20 IU/day), bodybuilders are compelled to co-administer exogenous insulin. The speaker presents this as a well-known practice within bodybuilding circles, used to counteract the metabolic disruption caused by supraphysiological GH doses. This stacking of GH with insulin is described as a reactive protocol necessity rather than a planned synergistic strategy.

As a direct consequence of the severe insulin resistance induced by supraphysiological GH doses (10–20 IU/day), bodybuilders are compelled to co-administer exogenous insulin in their protocols. The speaker presents this as a well-known practice within the bodybuilding community, used to counteract GH-driven insulin resistance. This stacking of GH with insulin is described as a reactive necessity rather than an intentional synergistic strategy.

The speaker references old-school bodybuilders' practice of manipulating exogenous insulin for anabolic purposes, explicitly stating he does not recommend this practice. He uses the death of a 17-year-old acquaintance as a case report-level warning. This is presented to contextualize why chronically elevated endogenous insulin is dangerous as a growth signal, drawing a parallel to the risks of exogenous peptide hormone manipulation.